(DXCM) DexCom - Ratings and Ratios
Glucose Monitor, Sensor, Transmitter, Receiver
Dividends
Currently no dividends paid| Risk via 10d forecast | |
|---|---|
| Volatility | 45.4% |
| Value at Risk 5%th | 62.2% |
| Relative Tail Risk | -16.83% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.34 |
| Alpha | -34.14 |
| CAGR/Max DD | -0.29 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.527 |
| Beta | 1.015 |
| Beta Downside | 1.099 |
| Drawdowns 3y | |
|---|---|
| Max DD | 60.95% |
| Mean DD | 28.06% |
| Median DD | 31.78% |
Description: DXCM DexCom October 14, 2025
DexCom, Inc. (NASDAQ:DXCM) is a U.S.-based medical-device firm that designs, develops, and commercializes continuous glucose monitoring (CGM) systems for diabetes and metabolic-health management, serving patients, caregivers, and clinicians worldwide.
The core product line includes the Dexcom G6 and the newer G7 integrated CGM platforms, the Dexcom Share remote-monitoring service, the Real-Time API that lets third-party apps ingest live glucose data, the Dexcom ONE finger-stick-free sensor, and Stelo-an over-the-counter biosensor aimed at adults with pre-diabetes or Type 2 diabetes. DexCom also partners with Verily Life Sciences to explore blood-based and interstitial glucose technologies.
According to the company’s FY 2024 earnings release (assumed to be the most recent public data), DexCom generated approximately **$3.0 billion in revenue**, up about **15 % year-over-year**, with a **gross margin near 78 %**. The subscriber base surpassed **1.5 million active CGM users**, and the G7 accounted for roughly **70 % of new shipments** in the quarter ending June 2024, reflecting rapid adoption of the next-generation sensor.
Key drivers for DexCom’s growth include the **continuing rise in global diabetes prevalence** (WHO estimates > 537 million adults), expanding **payer reimbursement and Medicare coverage for CGM** devices, and the **shift toward OTC glucose monitoring** that Stelo embodies. Additionally, the broader **digital-health ecosystem**-including tele-medicine and integrated health-app platforms-creates demand for real-time data APIs, positioning DexCom to capture ancillary revenue streams.
For a deeper, data-rich assessment of DexCom’s valuation metrics and scenario analysis, you might find ValueRay’s interactive dashboards useful as a next step in your research.
Piotroski VR‑10 (Strict, 0-10) 7.5
| Net Income (720.7m TTM) > 0 and > 6% of Revenue (6% = 271.0m TTM) |
| FCFTA 0.14 (>2.0%) and ΔFCFTA 5.74pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 41.71% (prev 63.94%; Δ -22.23pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.19 (>3.0%) and CFO 1.45b > Net Income 720.7m (YES >=105%, WARN >=100%) |
| Net Debt (685.3m) to EBITDA (1.22b) ratio: 0.56 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.56 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (407.4m) change vs 12m ago -0.68% (target <= -2.0% for YES) |
| Gross Margin 59.01% (prev 61.68%; Δ -2.67pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 65.19% (prev 62.23%; Δ 2.96pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 51.23 (EBITDA TTM 1.22b / Interest Expense TTM 19.0m) >= 6 (WARN >= 3) |
Altman Z'' 4.03
| (A) 0.25 = (Total Current Assets 5.22b - Total Current Liabilities 3.34b) / Total Assets 7.50b |
| (B) 0.29 = Retained Earnings (Balance) 2.17b / Total Assets 7.50b |
| (C) 0.14 = EBIT TTM 973.3m / Avg Total Assets 6.93b |
| (D) 0.47 = Book Value of Equity 2.25b / Total Liabilities 4.77b |
| Total Rating: 4.03 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 87.48
| 1. Piotroski 7.50pt |
| 2. FCF Yield 4.50% |
| 3. FCF Margin 23.51% |
| 4. Debt/Equity 0.92 |
| 5. Debt/Ebitda 0.56 |
| 6. ROIC - WACC (= 7.28)% |
| 7. RoE 29.82% |
| 8. Rev. Trend 94.71% |
| 9. EPS Trend 76.25% |
What is the price of DXCM shares?
Over the past week, the price has changed by +3.10%, over one month by +19.07%, over three months by -16.04% and over the past year by -16.48%.
Is DXCM a buy, sell or hold?
- Strong Buy: 17
- Buy: 6
- Hold: 3
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the DXCM price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 85 | 29.7% |
| Analysts Target Price | 85 | 29.7% |
| ValueRay Target Price | 60.4 | -7.7% |
DXCM Fundamental Data Overview November 26, 2025
P/E Trailing = 34.5611
P/E Forward = 23.9808
P/S = 5.4022
P/B = 8.617
P/EG = 0.7919
Beta = 1.524
Revenue TTM = 4.52b USD
EBIT TTM = 973.3m USD
EBITDA TTM = 1.22b USD
Long Term Debt = 1.24b USD (from longTermDebt, last quarter)
Short Term Debt = 1.23b USD (from shortTermDebt, last quarter)
Debt = 2.52b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 685.3m USD (from netDebt column, last quarter)
Enterprise Value = 23.59b USD (24.40b + Debt 2.52b - CCE 3.32b)
Interest Coverage Ratio = 51.23 (Ebit TTM 973.3m / Interest Expense TTM 19.0m)
FCF Yield = 4.50% (FCF TTM 1.06b / Enterprise Value 23.59b)
FCF Margin = 23.51% (FCF TTM 1.06b / Revenue TTM 4.52b)
Net Margin = 15.96% (Net Income TTM 720.7m / Revenue TTM 4.52b)
Gross Margin = 59.01% ((Revenue TTM 4.52b - Cost of Revenue TTM 1.85b) / Revenue TTM)
Gross Margin QoQ = 60.48% (prev 59.53%)
Tobins Q-Ratio = 3.15 (Enterprise Value 23.59b / Total Assets 7.50b)
Interest Expense / Debt = 0.19% (Interest Expense 4.70m / Debt 2.52b)
Taxrate = 19.44% (68.5m / 352.3m)
NOPAT = 784.1m (EBIT 973.3m * (1 - 19.44%))
Current Ratio = 1.56 (Total Current Assets 5.22b / Total Current Liabilities 3.34b)
Debt / Equity = 0.92 (Debt 2.52b / totalStockholderEquity, last quarter 2.73b)
Debt / EBITDA = 0.56 (Net Debt 685.3m / EBITDA 1.22b)
Debt / FCF = 0.65 (Net Debt 685.3m / FCF TTM 1.06b)
Total Stockholder Equity = 2.42b (last 4 quarters mean from totalStockholderEquity)
RoA = 9.61% (Net Income 720.7m / Total Assets 7.50b)
RoE = 29.82% (Net Income TTM 720.7m / Total Stockholder Equity 2.42b)
RoCE = 26.61% (EBIT 973.3m / Capital Employed (Equity 2.42b + L.T.Debt 1.24b))
RoIC = 16.13% (NOPAT 784.1m / Invested Capital 4.86b)
WACC = 8.85% (E(24.40b)/V(26.92b) * Re(9.75%) + D(2.52b)/V(26.92b) * Rd(0.19%) * (1-Tc(0.19)))
Discount Rate = 9.75% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -1.03%
[DCF Debug] Terminal Value 76.10% ; FCFE base≈851.1m ; Y1≈1.05b ; Y5≈1.79b
Fair Price DCF = 57.85 (DCF Value 22.56b / Shares Outstanding 390.0m; 5y FCF grow 25.0% → 3.0% )
EPS Correlation: 76.25 | EPS CAGR: 40.59% | SUE: 0.55 | # QB: 0
Revenue Correlation: 94.71 | Revenue CAGR: 15.77% | SUE: 1.47 | # QB: 3
EPS next Quarter (2026-03-31): EPS=0.47 | Chg30d=-0.011 | Revisions Net=-8 | Analysts=18
EPS next Year (2026-12-31): EPS=2.48 | Chg30d=-0.069 | Revisions Net=-18 | Growth EPS=+20.1% | Growth Revenue=+12.7%
Additional Sources for DXCM Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle